News

2021

Impressive new study results suggest potential new therapeutic use for Nexstim SmartFocus® nTMS in postsurgical rehabilitation of Paresis

17 May 2021

Confo Therapeutics awarded € 1 million VLAIO grant for pre-clinical development of CFTX-1554, an AT2R modulator for the treatment of neuropathic pain

30 March 2021

Nexstim gives an update on its promising treatment results of Major Depressive Disorder

12 March 2021

Mainstay Medical announces commercial launch of ReActiv8® in Australia

8 March 2021

Hologic acquires European Molecular diagnostic company Diagenode for approximately $159 million

1 March 2021

Mainstay Medical announces US$ 108 million equity financing transaction

16 February 2021

New study presents impressive results of Nexstim SmartFocus® nTMS Language Mapping

13 January 2021

2020

iSTAR Medical’s glaucoma device MINIject shows positive one-year results in European trial

16 November 2020

Confo Therapeutics announces selection of first product candidate and initiation of pre-clinical development

15 October 2020

Nexstim continues to report promising results in quickly growing number of patients completing SmartFocus® rTMS treatment of Major Depressive Disorder

5 October 2020

Positive outcomes for iSTAR Medical’s MIGS MINIject shown in trials of over 130 glaucoma patients

29 September 2020

Mainstay Medical announces US FDA approval of ReActiv8® Neurostimulation System for Chronic Low Back Pain

22 June 2020

• 1
• 2
• 3
• 4
• 5
• ...
• 6